Journal: Frontiers in Immunology
Article Title: Homoeriodictyol, targeting the bitter taste receptor TAS2R14, lowers the secretion of pro-inflammatory chemokines upon treatment with SARS-CoV-2 peptide pools in human peripheral blood mononuclear cells
doi: 10.3389/fimmu.2026.1771794
Figure Lengend Snippet: Chemokine secretion levels of (A) CXCL9 (n = 11), (B) CCL7 (n = 10), and (C) CCL2 (n = 10) of PMBCs, T-cells (T) and PBMCs depleted from CD3 + T-cells (w/oT) treated with PP for 24 h shown as fold-change to C per cell type; data is displayed as min to max box plot, all data points in the same treatment represent biological replicates of different donors; the same donors were used for comparison across different treatments; outlier test ROUT (Q = 1%); not all data normally distributed by Shapiro-Wilk test; non-parametric matched Friedman test, with post-hoc Dunn’s multiple comparisons test, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Article Snippet: The depletion of T-cells was carried out utilizing human CD3 + Micro Beads (Miltenyi Biotec) per the manufacturer’s protocol.
Techniques: Comparison